CN107440124A - 一种海藻胶为囊材的降血脂软胶囊制剂的制备方法 - Google Patents
一种海藻胶为囊材的降血脂软胶囊制剂的制备方法 Download PDFInfo
- Publication number
- CN107440124A CN107440124A CN201710944606.4A CN201710944606A CN107440124A CN 107440124 A CN107440124 A CN 107440124A CN 201710944606 A CN201710944606 A CN 201710944606A CN 107440124 A CN107440124 A CN 107440124A
- Authority
- CN
- China
- Prior art keywords
- capsule
- extract
- red ginseng
- preparation
- korean red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 52
- 239000000463 material Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 239000007901 soft capsule Substances 0.000 title claims abstract description 30
- 210000004369 blood Anatomy 0.000 title claims abstract description 29
- 239000008280 blood Substances 0.000 title claims abstract description 29
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 12
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 32
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 32
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 32
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 32
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 32
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 32
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 32
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 32
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 32
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 32
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 28
- 229920001817 Agar Polymers 0.000 claims abstract description 23
- 235000010419 agar Nutrition 0.000 claims abstract description 23
- 239000008272 agar Substances 0.000 claims abstract description 19
- 239000003292 glue Substances 0.000 claims abstract description 17
- 239000011162 core material Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims abstract description 12
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000661 sodium alginate Substances 0.000 claims abstract description 10
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 10
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 10
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 9
- 239000001923 methylcellulose Substances 0.000 claims abstract description 9
- 239000008367 deionised water Substances 0.000 claims abstract description 5
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 5
- 235000011187 glycerol Nutrition 0.000 claims abstract description 5
- 238000003825 pressing Methods 0.000 claims abstract description 5
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 5
- 229940073505 ethyl vanillin Drugs 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 239000006286 aqueous extract Substances 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 241001247821 Ziziphus Species 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract description 28
- 230000001093 anti-cancer Effects 0.000 abstract description 15
- 230000036039 immunity Effects 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 230000003712 anti-aging effect Effects 0.000 abstract description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract description 4
- 239000008279 sol Substances 0.000 abstract description 4
- 239000000811 xylitol Substances 0.000 abstract description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract description 4
- 235000010447 xylitol Nutrition 0.000 abstract description 4
- 229960002675 xylitol Drugs 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 abstract 1
- 235000010215 titanium dioxide Nutrition 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 25
- 235000013305 food Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 108010010803 Gelatin Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- 240000004371 Panax ginseng Species 0.000 description 9
- 235000008434 ginseng Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229920001543 Laminarin Polymers 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 5
- 239000005717 Laminarin Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000206672 Gelidium Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 coagulator Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000008440 Crataegus cuneata Nutrition 0.000 description 2
- 244000160089 Crataegus cuneata Species 0.000 description 2
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- AEMOLEFTQBMNLQ-ORRMXUGYSA-N (2s,3r,4r,5r,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical class O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-ORRMXUGYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000946389 Ecklonia kurome Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241001428166 Eucheuma Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- JZLUWZPEJDRDEO-UHFFFAOYSA-N [N].C1=CN=CN=C1 Chemical compound [N].C1=CN=CN=C1 JZLUWZPEJDRDEO-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 230000001121 heart beat frequency Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明所属保健食品研究开发技术领域。本发明涉及一种海藻胶为囊材的降血脂软胶囊制剂的制备方法。囊材原辅料组成为琼脂、甲基纤维素、海藻酸钠、乙基香兰醛,二氧化钛,丙三醇、山梨醇或木糖醇;将乳酸菌发酵高丽红参提取物和山楂微米级粉末及昆布、木耳和大枣的水提取物混合,即为囊心物;将囊材原辅料放入去离子水中,保持30分钟进行溶胶;0.5个真空度下脱气10‑12分钟,成为囊材胶液;将囊材胶液制胶片,加入囊心物,通过压制法制备软胶囊制剂。本发明产品囊材具有延伸性、张力强、韧性好的特点;软胶囊制剂具有降血脂、提高机体免疫力、延缓衰老和辅助抗癌的功能。
Description
技术领域:
本发明所属保健食品研究开发技术领域。本发明涉及一种海藻胶为囊材的降血脂软胶囊制剂的制备方法。本发明产品囊材具有延伸性、张力强、韧性好的特点;软胶囊制剂具有降血脂、提高机体免疫力、延缓衰老和辅助抗癌的功能。
背景技术:
软胶囊(Soft Capsule)自1935年问世以来已成为目前临床应用最广泛的药用制剂之一。许多油状,液状甚至膏状原料药均可加工成软胶囊剂。世界各国已上市的各类软胶囊制剂多达数百种,其中包括VE软胶囊、月见草软胶囊、多烯康软胶囊、深海鱼油软胶囊等常用的品种和形形色色的保健品制剂软胶囊(如鱼肝油软胶囊、锯叶棕油软胶囊等等)。软胶囊与硬胶囊一样均使用药用明胶为主要原料。明胶来自动物屠宰后的副产品(主要是猪、牛、羊骨以及猪皮和牛皮)。但90年代以来英国发生了震惊世界的疯牛病事件从而波及到明胶市场。因为欧洲人喜食牛肉,故牛骨与牛皮是欧洲明胶工业的主要原料。由于公众对疯牛病的普遍担心与恐慌,一些环保组织(如绿色和平组织)开始抵制来自牛副产品的明胶。与此同时,信奉伊斯兰教的国家要求进口明胶必须是″清真″的(即不能掺杂有猪皮和猪骨提取的明胶)。但实际上对于明胶生产厂来说,由于从各地收购的动物骨大多混杂堆放在一起,很难彻底分开,故要求生产明胶的原料绝对符合″清真″要求恐怕操作难度较大。在这种情况下,一些伊斯兰国家也抵制明胶软胶囊制剂的进口。这就给传统的软胶囊制剂产业造成很大冲击。寻找非动物来源的明胶替代产品作为软胶囊辅料已成为当务之急。此外由于明胶属于蛋白类物质,吸湿性强,并能把吸收的水分转移给内部药物,使药品吸潮变质,导致质量不合格和有效期短。
琼脂,学名琼胶,英文名(agar),又名洋菜(agar-agar)、琼胶、石花胶,是植物胶的一种,常用海产的麒麟菜、石花菜、江蓠等制成,为无色、无固定形状的固体,溶于热水。在食品工业中应用广泛,亦常用作细菌培养基。
琼脂是由海藻中提取的多糖体,是目前世界上用途最广泛的海藻胶之一。它在食品工业、医药工业、日用化工、生物工程等许多方面有着广泛的应用,琼脂用于食品中能明显改变食品的品质,提高食品的档次。价格很高。其特点:具有凝固性,稳定性,能与一些物质形成络合物等物理化学性质,可用作增稠剂,凝固剂,悬浮剂,乳化剂,保鲜剂和稳定剂。广泛用于制造粒粒橙及各种饮料,果冻,冰淇淋,糕点,软糖,罐头,肉制品,八宝粥,银耳燕窝,羹类食品,凉拌食品等等.琼脂在化学工业,医学科研,可作培养基,药膏基及其他用途。
用藻类制成的琼脂是半透明、无定形的粉末、薄片或颗粒。加工生产主要分布在山东、辽宁、广东各省均有加工生产。琼脂外形有细条、长条、薄片、小块等几种不同形体,以细条为佳。国外产地为日本、朝鲜、新西兰、美国和俄罗斯。琼脂不溶于冷水,能吸收相当本身体积20倍的水。易溶于沸水,稀释液在42℃(108°F)仍保持液状,但在37℃凝成紧密的胶冻。琼脂为细胞壁的组成成分,含有复杂的碳水化合物、钙与硫酸盐。
琼脂的最有用特性是它的凝点和熔点之间的温度相差很大。它在水中需加热至95℃时才开始熔化,熔化后的溶液温度需降到40℃时才开始凝固,所以它是配制固体培养基的最好凝固剂。用琼脂配制的固体培养基,可用以进行高温培养而不熔化,在凝固之前接种时,也不致将培养物烫死。因此,琼脂是制备各种生物培养基中应用最广泛的一种凝固剂。琼脂的浓度,通常是液体培养基的1~1.5%。
甲基纤维素甲基纤维素为白色或类白色纤维状或颗粒状粉末,无臭,无味。本品在水中溶胀成澄清或微浑浊的胶体溶液;在无水乙醇、氯仿或乙醚中不溶。甲基纤维素为白色或类白色纤维状或颗粒状粉末,无臭。平均分子量186.86n(n为聚合度),约18000~200000。性状:甲基纤维素在无水乙醇、乙醚、丙酮中几乎不溶。在80~90>;℃的热水中迅速分散、溶胀,降温后迅速溶解,水溶液在常温下相当稳定,高温时能凝胶,并且此凝胶能随温度的高低与溶液互相转变。具有优良的润湿性、分散性、粘接性、增稠性、乳化性、保水性和成膜性,以及对油脂的不透性。所成膜具有优良的韧性、柔曲性和透明度,因属非离子型,可与其他的乳化剂配伍,但易盐析,溶液在PH2-12范围内稳定。用作水溶性胶黏剂的增稠剂,如氯丁胶乳的增稠剂。也可用作氯乙烯、苯乙烯悬浮聚合的分散剂、乳化剂和稳定剂等。
海藻酸钠是从褐藻类的海带或马尾藻中提取的一种多糖碳水化合物,是由由d-L-甘露糖醛酸(M单元)与β-D-古罗糖醛酸(G单元)依靠1,4-糖苷键连接并由不同比例的GM、MM和GG片段组成的共聚物,是海藻酸衍生物中的一种,所以有时也称褐藻酸钠或海带胶和海藻胶。海藻酸钠以其良好的生物降解性和生物相容性,而被广泛应用于化学、生物、医药、食品等领域。
随着人们对植物胶囊的了解,以及国内外公众用药理念的转变,将会使植物来源胶囊的市场需求迅速增长。同时由于植物胶囊不使用任何明胶,广大穆斯林患者可以放心装药服用,产品可以出口到广大伊斯兰国家及犹太教地区,将为国家创收外汇,提高了企业的经济效益。
1高丽红参 系由产自韩国的高丽鲜参经蒸、烘烤加工而成,在加工高丽红参过程中,有新的抗癌活性成分产生。高丽红参不凉也不热,属于温性;高丽参虽性温但补性强,益气助火。高丽参又分白参和红参,脾虚火旺者宜用白参,因“生用气凉,微苦补阴”;脾虚肺怯者宜用红参,“熟用气温,味甘补阳”。总体来说,高丽参更适合老年气虚症状明显的人服用,能强壮体质,增强免疫力。
高丽红参的功效:
(1)益智健脑:对记忆力减退和运动协调能力下降的人以及经常喝酒或接触带乙醇成分的食物、药物的人,高丽红参具有提高脑力工作能力、增强记忆力和改善脑缺血性障碍的功效
(2)镇痛:一些专家通过做传感神经细胞试验发现,高丽参对身体各种疼痛症状都有所帮助。
(3)防癌和抗癌:高丽红参的皂苷成分和非皂苷成分有抑制多种癌细胞的增殖活性,同时也可抑制癌细胞转移。另外,高丽红参与抗癌剂同服用,抗癌效果要好于单独用抗癌剂(丝裂霉素)。这是因为肿瘤化疗中癌细胞易形成耐受,高丽红参与抗癌剂同服用,增强对癌细胞的杀伤力、减轻抗癌剂的副作用。
(4)增强免疫力:高丽红参提取物可恢复因服用具有免疫毒性的抗癌剂(丝裂霉素)而下降的细胞性免疫反应,尤其乙醚提取物可激活或增强细胞性免疫,及自然杀伤细胞的活性,对提高免疫力有很大的功效。
(5)控制糖尿病:高丽红参含有促进胰岛素分泌和类似胰岛素作用的物质,其中人参皂苷能改善高血糖,有效地控制糖尿病的发生。
(6)健肝:高丽参成分中有抗肝炎活性,具有解毒、保护肝脏及促进肝再生、恢复的作用。此外,高丽红参还有解酒、消除宿醉的作用。
(7)调节血压:高丽红参具有扩张血管作用,能改善血液循环,其中的皂苷成分通过促进血管内皮细胞释放一氧化氮,可达到降血压作用。
(8)抗疲劳及抗压:经研究发现,持续服用高丽红参可以提高运动能力和缓解疲劳,对促进运动员疲劳累积的恢复和预防运动性贫血有很大帮助;此外,高丽红参还可以增强对低温(5℃、O℃、-10℃)及高温(35℃)等不利环境的耐受力,通过对压力或环境变化进行精妙调节,提高抗压能力,维持机体稳定性。
(9)改善女性更年期障碍:据调查,有更年期障碍症状的女性在服用高丽红参后,有80%的人承认服用高丽红参后症状明显改善。专家称,这些女性如根据症状来调整用量,还可提高疗效。
(10)改善男性性功能障碍:高丽红参可防止因压力导致的男性性功能障碍。经临床试验,勃起障碍患者(90人)服用高丽红参后,在勃起程度、性欲及满意度等方面都有所改善。
(11)抗氧化及抗衰老:高丽红参具有抑制有害活性氧的增多和脂类过氧化的抗氧化效果。
(12)大补元气。
2昆布 昆布( Ecklonia Kurome Okem),昆布是褐藻门-海带目-翅藻科的一属,为北太平洋西部的暖水性藻类。主要分布在我国东海福建省平潭、莆田一带,浙江省鱼山中岛亦有分布。
(1)对甲状腺的作用:具作用是由于所含的碘、碘化物引起的。昆布可用来纠正由缺碘而引起的甲状腺机能不足,同时也可以暂时抑制甲状腺机能亢进的新陈代谢率而减轻症状,但不能持久,可作手术前的准备。碘化物进入组织及血液后,尚能促进病理产物如炎症渗出物的吸收,并能使病态的组织崩溃和溶解,故对活动性肺结核一般不用。昆布中所含之碘,较单纯的碘、碘化钾吸收慢,体内保留时间长,排出也慢。
(2)降压作用:海带氨酸(Laminine)具有降压作用,海带氨酸单枸橼酸盐对麻醉兔静脉注射,可使血压短暂下降,此作用不被阿托品阻断;它不影响闭塞二侧颈总动脉或注射去甲肾上腺素引起之升压反应;在体及离体试验中,它都能抑制心跳振幅,但不影响心跳频率。对平滑肌有较显著的抑制作用,如小肠、支气管等。并能对抗乙酰胆碱、5-羟色胺、氯化钡引起之收缩;在离体鼠小肠上,对抗乙酰胆碱之效力为罂粟碱的0.8%。在离体豚鼠输精管上能增强去甲肾上腺素的作用。对蛙腹直肌之作用很弱。海带氨酸单盐酸盐亦能降压并抑制离体兔肠;但对离体兔心有轻度兴奋作用。
(3)降血糖作用:昆布中所含褐藻淀粉30ml/kg灌胃对正常小鼠有明显的降血糖作用,剂量达100mg/kg时,7小时后血糖降低49%。褐藻酸钠的降血糖作用较差,灌胃无效,100mg/kg腹腔注射才有明显降血糖果作用,剂量达300m/kg时,7小时血糖可降低38%。对四氮嘧啶性高血糖,褐藻淀粉300mg/kg灌胃,24小时后血糖降低61%;褐藻酸钠300mg/kg腹腔注射;血糖降低39%,而灌胃无效。其他作用见海藻条。
(4)降血脂和抗凝作用:海带多糖多次灌胃,能明显地抑制高血脂鸡血清总胆固醇、甘油三酯的含量上升,并能减少鸡主动脉内膜粥样斑块的形成及发展。海带多糖在体内外均有抗凝血作用,其抗凝活性为7肝素u/mg。因不少冠心病患者除有高血脂外,其血液常处于高凝状态。因此,海带多糖同时具有降血脂和抗凝作用,对临床有一定意义。
(5)抗放射作用:海带多糖1次注射,能明显地提高900拉德照射小鼠存活率,并随给药剂量增加存活率提高,能显著地保护照射动物的造血组织。因此,海带多糖对于预防放疗所致造血组织损伤,刺激造血恢复及增强癌症患者的免疫功能,合并放射治疗可能有一定实际意义。
3木耳 木耳,为木耳属的食用菌。木耳的功效与作用:
(1)补气血 木耳被营养学家誉为‘素中之荤’和‘素中之王’,每100克黑木耳中含铁185毫克,它比绿叶蔬菜中含铁量最高的菠菜高出20倍,比动物性食品中含铁量最高的猪肝还高出约7倍,是各种荤素食品中含铁量最多养血驻颜,令人肌肤红润,容光焕发,并可防治缺铁性贫血;减少血小板凝块,预防血栓的发生,预防动脉粥样硬化和冠心病的发生。
(2)减肥防癌治便秘 能够促进胃肠蠕动,促进肠道脂肪食物的排泄、减少食物中脂肪的吸收,从而防止肥胖;同时,由于这两种物质能促进胃肠蠕动,防止便秘,有利于体内大便中有毒物质的及时清除和排出,从而起到预防直肠癌及其它消化系统癌症的作用。所以,老年人特别是有便秘习惯的老年人,坚持食用黑木耳,常食木耳粥,对预防多种老年疾病、抗癌、防癌,延缓衰老都有良好的效果。
(3)清肠胃 木耳可以把残留在人体消化系统内的灰尘、杂质吸附集中起来排出体外,从而起到清胃涤肠的作用,它对胆结石、肾结石等内源性异物也有比较显著的化解功能。
4山楂 山楂也叫山里红,为蔷薇科植物山里红或山楂的干燥成熟果实。山楂有很高的营养价值和医疗价值,老年人常吃山楂制品能增强食欲,改善睡眠,保持骨骼和血液中钙的恒定,预防动脉粥样硬化,因此山楂被视为“长寿食品”。
(1)降压作用:山楂有扩张外周血管并具有持久的降压作用,尤其对冷血动物的降压作用持续时间最长,当山楂与决乌汤合用时,其降压作用大为增强,并且作用时间也有所延长。
(2)抗心肌缺血:山楂总黄酮能减轻缺血再灌注损伤心肌心电图的ST段变化,提高血清NO的浓度,降低心肌缺血再灌注时心肌组织丙二醛(MDA)的水平。山楂聚合黄酮能缩小兔实验性心肌梗死范围。文献报道,山楂提取物可以抑制缺血再灌注大鼠血清中(LDH)的升高,提高SOD的活力,降低MDA的生成量,从而保护心肌,减轻缺血再灌注导致的心肌细胞损伤。
(3)调血脂作用:山楂总黄酮表现出显著的调血脂作用,对高脂血症所致大鼠血管功能损伤具有明显保护作用,陈志谦用山楂配合决乌汤治疗血脂异常病人65例表明,治疗后TC、LDL-C显著下降,治疗前后比较,差异均有非常显著的意义,其有效率达89.2%。
(4)抗脑缺血作用:山楂叶总黄酮可明显提高模型小鼠脑组织LDH及SOD活力,对局灶性脑缺血再灌注损伤小鼠脑组织有明显的保护作用,其机制与抗氧化有关。
(5)对血液流变学作用:山楂总黄酮3个剂量(80、40、20g/kg)均有降低急性血瘀模型大鼠全血比黏度、血浆黏度和红细胞压积的活血化瘀作用。山楂醇提取物对中、低切全血比黏度有显著降低作用。
(6)对血管内皮细胞的作用:不同剂量的山楂对氧化修饰的低密度脂蛋白引起的人脐静脉内皮细胞(EC)损伤和对EC的直接作用表明,山楂能抑制低密度脂蛋白的氧化修饰,减少脂质过氧化物的形成,阻断有害物质的产生,可通过直接作用于内皮细胞,调节内皮细胞功能,增强内皮细胞对有害因子的抵抗力和耐受性,从而保护内皮细胞免受损害。
(7)消化系统作用:山楂可单味应用,亦可与神曲、麦芽、莱菔子等配伍,加强消食化积之功。其含维生素C、维生素B、胡萝卜素及多种有机酸,口服能增加胃中消化酶的分泌,所含蛋白酶、脂肪酸,可促进肉食分解消化。
(8)糖代谢及抗氧化作用:应用6%的山楂水煎剂可明显降低高脂饮食大鼠空腹血清胰岛素和MDA水平,表明其可改善高脂饮食大鼠的胰岛素血症,增强机体抗脂质氧化作用,其机制可能与调节糖代谢有关,其药效物质基础可能与金丝桃苷和熊果酸有关。
山楂具药食双重价值,我国盛产山楂,资源丰富,经济物廉。近几年来,其在心脑血管系统疾病中的防治作用成为许多学者的研究热点,有希望开发成为新型的防治心脑血管系统疾病的药物。不仅可将山楂开发成各种保健品,还可提取活性成分,制成制剂用于临床,有着广阔的开发前景。
5大枣 又名红枣、干枣、枣子,起源于中国,在中国已有八千多年的种植历史,自古以来就被列为“五果”(栗、桃、李、杏、枣)之一。大枣富含蛋白质、脂肪、糖类、胡萝卜素、B族维生素、维生素C、维生素P以及钙、磷、铁和环磷酸腺苷等营养成分。其中维生素C的含量在果品中名列前茅,有维生素王之美称。据国外的一项临床研究显示:连续吃大枣的病人,健康恢复比单纯吃维生素药剂快3倍以上。红枣所含有的环磷酸腺苷是人体细胞能量代谢的必需成分,能够增强肌力、消除疲劳、扩张血管、增加心肌收缩力、改善心肌营养,对防治心血管系统疾病有良好的作用;中医中药理论认为,红枣对慢性肝炎、肝硬化、贫血、过敏性紫癜等病症有较好疗效;红枣含有三萜类化合物及环磷酸腺苷,有较强的抗癌、抗过敏作用。
发明内容:
1、一种海藻胶为囊材的降血脂软胶囊制剂的制备方法,其特征如下:
(1)囊材原辅料组成及重量为琼脂1.0-3.0kg、甲基纤维素0.3-1.0kg、海藻酸钠0.2-0.4kg、乙基香兰醛0.01-0.02kg,二氧化钛0.02-0.03kg,丙三醇0.1-0.2kg、山梨醇或木糖醇0.1-0.2kg;
(2)囊心物原辅料重量为高丽红参60-90g、昆布60-90g、木耳60-90g、山楂30-60g、大枣30-60g;
(3)将(2)中的高丽红参进行水提取3-4次,每次加水量为高丽红参重量的6-8倍,时间为每次3-4h,60-80℃,得到水提取液,合并,60-80℃减压浓缩至每毫升水提取液相当于含有1g高丽红参的量,即为高丽红参浸膏;
(4)将(3)中高丽红参浸膏,加入葡萄糖120-180g、乳酸菌3-9g,在39-43℃发酵72-96h,得到乳酸菌发酵高丽红参提取物,60-80℃减压浓缩、干燥,混匀;
(5)将(2)中的山楂通过胶体磨或振动磨或气流磨将其粉碎为微米级粉末,混匀;
(6)将(2)中的昆布、木耳和大枣进行水提取3-4次,每次加水量为昆布、木耳和大枣总重的6-8倍,时间为每次3-4h,60-80℃,得到昆布、木耳和大枣水提取液,合并,60-80℃减压浓缩、干燥,混匀,即为昆布、木耳和大枣的水提取物;
(7)将(4)中乳酸菌发酵高丽红参提取物和(5)中山楂微米级粉末及(6)中昆布、木耳和大枣的水提取物混合,即为囊心物;
(8)将(1)中囊材原辅料放入7.0-8.5kg的去离子水中,在85-90℃下保持30分钟进行溶胶;85-90℃0.5个真空度下脱气10-12分钟,成为囊材胶液;
(9)将(8)中囊材胶液制胶片,加入(7)中囊心物,通过压制法制备软胶囊制剂。
本发明的目的在于提供一种海藻胶为囊材的降血脂软胶囊制剂的制备方法,囊材具有延伸性、张力强、韧性好的特点;软胶囊制剂具有降血脂、提高机体免疫力、延缓衰老和辅助抗癌的功能。
具体实施方案:
本发明所述的一种海藻胶为囊材的降血脂软胶囊制剂的制备方法包括以下实施例,下面的实施例可进一步说明本发明,但不以任何方式限制本发明。
实施例1:
1、一种海藻胶为囊材的降血脂软胶囊制剂的制备方法,其特征如下:
(1)囊材原辅料组成及重量为琼脂1.0kg、甲基纤维素0.3kg、海藻酸钠0.2kg、乙基香兰醛0.01kg,二氧化钛0.02kg,丙三醇0.1kg、山梨醇或木糖醇0.1kg;
(2)囊心物原辅料重量为高丽红参60g、昆布60g、木耳60g、山楂30g、大枣30g;
(3)将(2)中的高丽红参进行水提取3次,每次加水量为高丽红参重量的6倍,时间为每次3h,60℃,得到水提取液,合并,60℃减压浓缩至每毫升水提取液相当于含有1g高丽红参的量,即为高丽红参浸膏;
(4)将(3)中高丽红参浸膏,加入葡萄糖120g、乳酸菌3g,在39℃发酵96h,得到乳酸菌发酵高丽红参提取物,60℃减压浓缩、干燥,混匀;
(5)将(2)中的山楂通过胶体磨或振动磨或气流磨将其粉碎为微米级粉末,混匀;
(6)将(2)中的昆布、木耳和大枣进行水提取3次,每次加水量为昆布、木耳和大枣总重的6倍,时间为每次3h,60℃,得到昆布、木耳和大枣水提取液,合并,60℃减压浓缩、干燥,混匀,即为昆布、木耳和大枣的水提取物;
(7)将(4)中乳酸菌发酵高丽红参提取物和(5)中山楂微米级粉末及(6)中昆布、木耳和大枣的水提取物混合,即为囊心物;
(8)将(1)中囊材原辅料放入7.0kg的去离子水中,在85℃下保持30分钟进行溶胶;85℃0.5个真空度下脱气10分钟,成为囊材胶液;
(9)将(8)中囊材胶液制胶片,加入(7)中囊心物,通过压制法制备软胶囊制剂。
实施例2:
1、一种海藻胶为囊材的降血脂软胶囊制剂的制备方法,其特征如下:
(1)囊材原辅料组成及重量为琼脂3.0kg、甲基纤维素1.0kg、海藻酸钠0.4kg、乙基香兰醛0.02kg,二氧化钛0.03kg,丙三醇0.2kg、山梨醇或木糖醇0.2kg;
(2)囊心物原辅料重量为高丽红参90g、昆布90g、木耳90g、山楂60g、大枣60g;
(3)将(2)中的高丽红参进行水提取4次,每次加水量为高丽红参重量的8倍,时间为每次4h,80℃,得到水提取液,合并,80℃减压浓缩至每毫升水提取液相当于含有1g高丽红参的量,即为高丽红参浸膏;
(4)将(3)中高丽红参浸膏,加入葡萄糖180g、乳酸菌9g,在43℃发酵72h,得到乳酸菌发酵高丽红参提取物,80℃减压浓缩、干燥,混匀;
(5)将(2)中的山楂通过胶体磨或振动磨或气流磨将其粉碎为微米级粉末,混匀;
(6)将(2)中的昆布、木耳和大枣进行水提取4次,每次加水量为昆布、木耳和大枣总重的8倍,时间为每次4h,80℃,得到昆布、木耳和大枣水提取液,合并,80℃减压浓缩、干燥,混匀,即为昆布、木耳和大枣的水提取物;
(7)将(4)中乳酸菌发酵高丽红参提取物和(5)中山楂微米级粉末及(6)中昆布、木耳和大枣的水提取物混合,即为囊心物;
(8)将(1)中囊材原辅料放入8.5kg的去离子水中,在90℃下保持30分钟进行溶胶;90℃0.5个真空度下脱气12分钟,成为囊材胶液;
(9)将(8)中囊材胶液制胶片,加入(7)中囊心物,通过压制法制备软胶囊制剂。
Claims (1)
1.一种海藻胶为囊材的降血脂软胶囊制剂的制备方法,其特征如下:
(1)囊材原辅料组成及重量为琼脂1.0-3.0kg、甲基纤维素0.3-1.0kg、海藻酸钠0.2-0.4kg、乙基香兰醛0.01-0.02kg,二氧化钛0.02-0.03kg,丙三醇0.1-0.2kg、山梨醇或木糖醇0.1-0.2kg;
(2)囊心物原辅料重量为高丽红参60-90g、昆布60-90g、木耳60-90g、山楂30-60g、大枣30-60g;
(3)将(2)中的高丽红参进行水提取3-4次,每次加水量为高丽红参重量的6-8倍,时间为每次3-4h,60-80℃,得到水提取液,合并,60-80℃减压浓缩至每毫升水提取液相当于含有1g高丽红参的量,即为高丽红参浸膏;
(4)将(3)中高丽红参浸膏,加入葡萄糖120-180g、乳酸菌3-9g,在39-43℃发酵72-96h,得到乳酸菌发酵高丽红参提取物,60-80℃减压浓缩、干燥,混匀;
(5)将(2)中的山楂通过胶体磨或振动磨或气流磨将其粉碎为微米级粉末,混匀;
(6)将(2)中的昆布、木耳和大枣进行水提取3-4次,每次加水量为昆布、木耳和大枣总重的6-8倍,时间为每次3-4h,60-80℃,得到昆布、木耳和大枣水提取液,合并,60-80℃减压浓缩、干燥,混匀,即为昆布、木耳和大枣的水提取物;
(7)将(4)中乳酸菌发酵高丽红参提取物和(5)中山楂微米级粉末及(6)中昆布、木耳和大枣的水提取物混合,即为囊心物;
(8)将(1)中囊材原辅料放入7.0-8.5kg的去离子水中,在85-90℃下保持30分钟进行溶胶;85-90℃0.5个真空度下脱气10-12分钟,成为囊材胶液;
(9)将(8)中囊材胶液制胶片,加入(7)中囊心物,通过压制法制备软胶囊制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710944606.4A CN107440124A (zh) | 2017-10-11 | 2017-10-11 | 一种海藻胶为囊材的降血脂软胶囊制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710944606.4A CN107440124A (zh) | 2017-10-11 | 2017-10-11 | 一种海藻胶为囊材的降血脂软胶囊制剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107440124A true CN107440124A (zh) | 2017-12-08 |
Family
ID=60497631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710944606.4A Withdrawn CN107440124A (zh) | 2017-10-11 | 2017-10-11 | 一种海藻胶为囊材的降血脂软胶囊制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107440124A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552422A (zh) * | 2003-12-18 | 2004-12-08 | 华东中药工程集团有限公司 | 益母草软胶囊及其制备方法 |
CN101069678A (zh) * | 2007-06-15 | 2007-11-14 | 广东富味制果厂有限公司 | 一种软胶囊及其制备方法 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN104337779A (zh) * | 2013-07-31 | 2015-02-11 | 山东大学(威海) | 一种海藻胶及琼脂为囊材的滴丸及其生产工艺 |
CN104338142A (zh) * | 2013-07-31 | 2015-02-11 | 山东大学(威海) | 一种海藻多糖及亚麻胶为囊材的滴丸及其生产工艺 |
CN104770512A (zh) * | 2014-01-11 | 2015-07-15 | 山东大学(威海) | 一种西洋红参茶的制备方法 |
CN105495414A (zh) * | 2016-01-04 | 2016-04-20 | 环翠楼红参生物科技股份有限公司 | 一种高丽红参芝麻抗衰老功能食品的制备方法 |
CN105533415A (zh) * | 2016-01-04 | 2016-05-04 | 环翠楼红参生物科技股份有限公司 | 一种高丽红参小麦胚芽抗氧化功能食品的制备方法 |
CN105595337A (zh) * | 2016-01-08 | 2016-05-25 | 福建农林大学 | 一种辅助降血糖海藻胶软胶囊及其制备方法 |
-
2017
- 2017-10-11 CN CN201710944606.4A patent/CN107440124A/zh not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552422A (zh) * | 2003-12-18 | 2004-12-08 | 华东中药工程集团有限公司 | 益母草软胶囊及其制备方法 |
CN101069678A (zh) * | 2007-06-15 | 2007-11-14 | 广东富味制果厂有限公司 | 一种软胶囊及其制备方法 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN104337779A (zh) * | 2013-07-31 | 2015-02-11 | 山东大学(威海) | 一种海藻胶及琼脂为囊材的滴丸及其生产工艺 |
CN104338142A (zh) * | 2013-07-31 | 2015-02-11 | 山东大学(威海) | 一种海藻多糖及亚麻胶为囊材的滴丸及其生产工艺 |
CN104770512A (zh) * | 2014-01-11 | 2015-07-15 | 山东大学(威海) | 一种西洋红参茶的制备方法 |
CN105495414A (zh) * | 2016-01-04 | 2016-04-20 | 环翠楼红参生物科技股份有限公司 | 一种高丽红参芝麻抗衰老功能食品的制备方法 |
CN105533415A (zh) * | 2016-01-04 | 2016-05-04 | 环翠楼红参生物科技股份有限公司 | 一种高丽红参小麦胚芽抗氧化功能食品的制备方法 |
CN105595337A (zh) * | 2016-01-08 | 2016-05-25 | 福建农林大学 | 一种辅助降血糖海藻胶软胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101664184A (zh) | 一种降血脂的保健品及其制作方法 | |
CN101664136A (zh) | 一种高活性营养纳豆的制备方法及其应用 | |
CN114796441A (zh) | 针对风寒湿痹型风湿、类风湿关节炎的营养剂及制备方法 | |
CN105533688A (zh) | 一种辅助降血糖保健软胶囊及其制备方法 | |
CN105707876B (zh) | 一种具有稳定和溶解斑块的饮食组合物及其制备方法和用途 | |
KR20100067575A (ko) | 해조류 매생이를 함유하는 공진환의 제조 | |
CN103431276A (zh) | 一种供炎性肠病患者食用的五谷杂粮全营养配方食品 | |
CN109699890A (zh) | 一种能缓解痛风和高尿酸的草本植物制剂 | |
CN107412713A (zh) | 治疗自体免疫性与免疫相关性疾病的中成药、医疗食品及制备方法 | |
CN107594526A (zh) | 一种海藻胶为囊材的助消化软胶囊制剂的制备方法 | |
CN105029160A (zh) | 一种茶香风味粉皮及其制备方法 | |
CN109549206A (zh) | 一种溶栓及预防心血管疾病的功能性食品及其制备方法 | |
CN107440124A (zh) | 一种海藻胶为囊材的降血脂软胶囊制剂的制备方法 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
KR102198434B1 (ko) | 천연식물을 이용한 고지혈증 예방 또는 치료용 약학 조성물, 그 제조방법 및 제제 | |
CN107692087A (zh) | 一种辅助降压的海参肠保健食品 | |
CN106804810A (zh) | 一种八仙草清热解毒茶冻及其制备方法 | |
CN106729518A (zh) | 一种降血压的茶饮料及其制备方法与应用 | |
CN107495376A (zh) | 一种海藻胶为囊材的抗疲劳软胶囊制剂的制备方法 | |
CN107712894A (zh) | 一种海藻胶为囊材的降胆固醇软胶囊制剂的制备方法 | |
KR20210058030A (ko) | 약초식혜와 l-아르기닌을 주원료로 하는 음료조성물의 제조방법 | |
CN108783443A (zh) | 一种用于脏腑调理的片剂及其制备方法 | |
CN112076305A (zh) | 一种治疗人体代谢症候群及杀菌消炎的中药制内服外用原液合剂 | |
CN103610123A (zh) | 一种海参和蛋白小球藻浆液制品及其制备方法 | |
WO2005094858A1 (ja) | 抗糖尿病用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171208 |